A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors

Sponsor
Tianjin First Central Hospital
Study ID
NCT07173244
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Adebrelimab — DRUG
    adebrelimab-based regimen

Study Details

This prospective, multicenter, non-interventional, observational, real-world study was designed to evaluate the safety and efficacy of an adebrelimab-based regimen in patients with advanced solid tumors.

Key Dates

First listed
Sep 15, 2025
Start date
Sep 15, 2025
Status verified
Sep 2025
Primary completion
Sep 30, 2027
Completion
Sep 30, 2029

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Arm 1
    adebrelimab-based regimen

Primary Outcome Measure

The rate of treatment-related adverse reactions(TRAE)/immunotherapy-related adverse reactions/(irAE) and grade ≥ 3 TRAE/irAE [ Time Frame: Through study completion, an average of 1 year ]

Central Contacts

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies